Contrast-enhanced ultrasound detected portal vein thrombosis far better than CT in cases complicating hepatocellular carcinoma. While CT found only 68% of thrombi, contrast-enhanced ultrasound identified every one in the study. It also did a far better job of helping determine if they were malignant.
Contrast-enhanced ultrasound detected portal vein thrombosis far better than CT in cases complicating hepatocellular carcinoma. While CT found only 68% of thrombi, contrast-enhanced ultrasound identified every one in the study. It also did a far better job of helping determine if they were malignant.
Dr. Sandro Rossi and colleagues at the IRCCS Policlinico "S. Matteo" in Golgi, Italy, and Sunnybrook Health Science Centre in Toronto studied 50 patients diagnosed with hepatocellular carcinoma complicated by portal vein thrombosis. They published their study in European Radiology, which made it available online March 28.
In 37 cases, the thrombi involved segmental branches. The other 13 cases involved the main portal trunk. Each diagnosis was confirmed with biopsy, which also showed that 44 of the 50 thrombi were malignant.
Researchers performed CT scans and contrast-enhanced ultrasound exams the same week as the corresponding biopsies. Experienced readers under blinded conditions checked each exam for the presence of portal vein thrombosis and rated findings as either malignant or benign.
The researchers then compared these ratings with the biopsy results to determine accuracy. CT exams detected only 34 of the 50, or 68% of thrombi. Readers correctly characterized the malignancy of only 23 of these 34, or 68%.
Contrast-enhanced ultrasound detected all 50, or 100%, of thrombi. Readers correctly characterized the malignancy of 49 of the 50, or 98%.
The researchers concluded that contrast-enhanced ultrasound is significantly superior to CT when used in detecting and characterizing portal vein thrombosis as a complication of hepatocellular carcinoma. They recommend its use in the staging of these tumors.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What New Research Reveals About ChatGPT and Ultrasound Detection of Thyroid Nodules
March 13th 2024In a comparison of image-to-text large language models (LLMs), ChatGPT 4.0 offered a 95 percent sensitivity rate and an 83 percent AUC that were comparable to that of two senior radiologists and one junior radiologist interacting with LLM to differentiate between malignant and benign thyroid nodules on ultrasound.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.